KMDA
Price
$8.01
Change
-$0.18 (-2.20%)
Updated
Feb 4, 02:45 PM (EDT)
Capitalization
474M
42 days until earnings call
Intraday BUY SELL Signals
SIGA
Price
$6.61
Change
-$0.34 (-4.89%)
Updated
Feb 4, 03:17 PM (EDT)
Capitalization
498.06M
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KMDA vs SIGA

Header iconKMDA vs SIGA Comparison
Open Charts KMDA vs SIGABanner chart's image
Kamada
Price$8.01
Change-$0.18 (-2.20%)
Volume$200
Capitalization474M
SIGA Technologies
Price$6.61
Change-$0.34 (-4.89%)
Volume$200
Capitalization498.06M
KMDA vs SIGA Comparison Chart in %
KMDA
Daily Signal:
Gain/Loss:
SIGA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
KMDA vs. SIGA commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and SIGA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (KMDA: $8.19 vs. SIGA: $6.95)
Brand notoriety: KMDA and SIGA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 66% vs. SIGA: 104%
Market capitalization -- KMDA: $474M vs. SIGA: $498.06M
KMDA [@Pharmaceuticals: Generic] is valued at $474M. SIGA’s [@Pharmaceuticals: Generic] market capitalization is $498.06M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.79B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileSIGA’s FA Score has 3 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • SIGA’s FA Score: 3 green, 2 red.
According to our system of comparison, SIGA is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 4 TA indicator(s) are bullish while SIGA’s TA Score has 5 bullish TA indicator(s).

  • KMDA’s TA Score: 4 bullish, 5 bearish.
  • SIGA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SIGA is a better buy in the short-term than KMDA.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а -7.67% price change this week, while SIGA (@Pharmaceuticals: Generic) price change was +1.91% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.83%. For the same industry, the average monthly price growth was -2.35%, and the average quarterly price growth was +12.98%.

Reported Earning Dates

KMDA is expected to report earnings on Mar 18, 2026.

SIGA is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.83% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SIGA($498M) and KMDA($474M) have the same market capitalization . KMDA has higher P/E ratio than SIGA: KMDA (23.37) vs SIGA (6.75). KMDA YTD gains are higher at: 16.006 vs. SIGA (13.748). SIGA has higher annual earnings (EBITDA): 90.8M vs. KMDA (37.2M). SIGA has more cash in the bank: 172M vs. KMDA (72M). SIGA has less debt than KMDA: SIGA (583K) vs KMDA (11.5M). KMDA (175M) and SIGA (172M) have equivalent revenues.
KMDASIGAKMDA / SIGA
Capitalization474M498M95%
EBITDA37.2M90.8M41%
Gain YTD16.00613.748116%
P/E Ratio23.376.75346%
Revenue175M172M102%
Total Cash72M172M42%
Total Debt11.5M583K1,973%
FUNDAMENTALS RATINGS
KMDA vs SIGA: Fundamental Ratings
KMDA
SIGA
OUTLOOK RATING
1..100
8016
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
7092
SMR RATING
1..100
7623
PRICE GROWTH RATING
1..100
4354
P/E GROWTH RATING
1..100
6020
SEASONALITY SCORE
1..100
829

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SIGA's Valuation (2) in the Pharmaceuticals Other industry is significantly better than the same rating for KMDA (75) in the Biotechnology industry. This means that SIGA’s stock grew significantly faster than KMDA’s over the last 12 months.

KMDA's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as SIGA (92) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to SIGA’s over the last 12 months.

SIGA's SMR Rating (23) in the Pharmaceuticals Other industry is somewhat better than the same rating for KMDA (76) in the Biotechnology industry. This means that SIGA’s stock grew somewhat faster than KMDA’s over the last 12 months.

KMDA's Price Growth Rating (43) in the Biotechnology industry is in the same range as SIGA (54) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to SIGA’s over the last 12 months.

SIGA's P/E Growth Rating (20) in the Pharmaceuticals Other industry is somewhat better than the same rating for KMDA (60) in the Biotechnology industry. This means that SIGA’s stock grew somewhat faster than KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDASIGA
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
59%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
65%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 16 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signal:
Gain/Loss:
SIGA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LCMNX9.510.04
+0.42%
Miller Income C
CFWCX28.370.03
+0.11%
Calvert Global Water C
FGRSX46.69N/A
N/A
Federated Hermes Intl Leaders R6
JEPSX14.52-0.03
-0.21%
JPMorgan Equity Premium Income R5
VIKSX9.94-0.23
-2.26%
Virtus KAR Small-Mid Cap Growth I

KMDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KMDA has been loosely correlated with LFCR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if KMDA jumps, then LFCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
-0.61%
LFCR - KMDA
35%
Loosely correlated
-6.46%
TEVA - KMDA
31%
Poorly correlated
+2.06%
SGIOY - KMDA
27%
Poorly correlated
+2.07%
OGI - KMDA
27%
Poorly correlated
+3.97%
CRDL - KMDA
25%
Poorly correlated
+6.17%
More

SIGA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SIGA has been loosely correlated with EBS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SIGA jumps, then EBS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SIGA
1D Price
Change %
SIGA100%
N/A
EBS - SIGA
43%
Loosely correlated
-1.45%
TKNO - SIGA
30%
Poorly correlated
+2.95%
AMLX - SIGA
29%
Poorly correlated
-1.23%
COLL - SIGA
29%
Poorly correlated
+0.85%
KMDA - SIGA
28%
Poorly correlated
-0.61%
More